Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.
暂无分享,去创建一个
L. Kalish | T. Quinn | J. Lew | J. Pitt | J. Moye | C. Zorrilla | H. Minkoff | H. Minkoff | S. Burchett | C. Hanson | P. Garcia | J. Kornegay | B. Jackson
[1] J. Read,et al. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies: the International Perinatal HIV Group , 1999 .
[2] F. Parazzini. Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial , 1999, The Lancet.
[3] D. Levy,et al. Surveillance for waterborne-disease outbreaks--United States, 1995-1996. , 1998, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.
[4] A. Berrebi,et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. , 1998, JAMA.
[5] Roger Detels,et al. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.
[6] L. Kalish,et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. , 1997, The New England journal of medicine.
[7] C. Macken,et al. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant , 1997, Nature Medicine.
[8] C. Rouzioux,et al. Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant , 1997 .
[9] L. Kalish,et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. , 1996, The Journal of infectious diseases.
[10] J L Sullivan,et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1996, The New England journal of medicine.
[11] A. Adimora,et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. , 1996, JAMA.
[12] L. Mofenson,et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission , 1996, AIDS.
[13] M. Sim,et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. , 1996, JAMA.
[14] D. Hom,et al. Maternal HIV-1 RNA serum levels at delivery and vertical transmission in Uganda. , 1996, Pediatric AIDS and HIV infection.
[15] P. Stratton,et al. The Women and Infants Transmission Study (WITS) of Maternal-Infant HIV Transmission: Study Design, Methods, and Baseline Data , 1996 .
[16] O. Weislow,et al. Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] Martha Barry,et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Connor E, Sperling R, Gelber R, et al. N Engl J Med 1994; 331: 1173-9 , 1995 .
[18] R. Gelber,et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.
[19] S. Nachman,et al. Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Gelman,et al. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. , 1993, Cytometry.
[21] D. Wara,et al. Proposed definitions for in utero versus intrapartum transmission of HIV-1. , 1992, The New England journal of medicine.
[22] E. Baráth,et al. Fundamentals of Biostatistics. , 1992 .
[23] J. Bremer,et al. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories , 1992, Journal of clinical microbiology.
[24] D. Hosmer,et al. Applied Logistic Regression , 1991 .
[25] M. Salimans,et al. Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.
[26] Nathan Mantel,et al. Chi-square tests with one degree of freedom , 1963 .
[27] C. Katlama,et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. , 1997, The Journal of infectious diseases.